secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0000882095-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised
--------------------------------------------------------------------------------

- GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.
- Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.
- Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.
- Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.
- Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/0000882095-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/gild-20251030.htm
  HTML page:      https://secwatch.observer/filing/0000882095-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer